Strides Pharma Science Ltd (STAR) AI Stock Analysis

• Market Cap: ₹79.05B
• Dividend Yield: 0.47%
• Average Volume (3M): 15.20K
• Price to Earnings (P/E): 21.8
• Beta (1Y): 1.20
• Revenue Growth: 10.84%
• EPS Growth: N/A
• Country: IN
• Employees: 3,065
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 10.80
• Shares Outstanding: 92,172,714
• 10 Day Avg. Volume: 14,233
• 30 Day Avg. Volume: 15,196
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹918.00
• Price Target Upside: 8.59% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 64 Neutral
• Price Target: ₹918.00 ▲(8.59% Upside)

The overall stock score of 64 reflects a balanced view of Strides Pharma Science Ltd's financial recovery and technical indicators. The company's improving financial performance is a significant strength, while technical analysis suggests potential short-term challenges. Valuation metrics indicate the stock is fairly valued, with limited dividend appeal. The absence of earnings call and corporate events data means these factors do not influence the score.

Strides Pharma Science Ltd Business Overview & Revenue Model

Company Description

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.

How the Company Makes Money

Strides Pharma Science Ltd generates revenue through several key streams. The primary source of income is the sale of generic pharmaceuticals, where the company capitalizes on its large portfolio of products in various therapeutic segments. Another significant revenue stream is its institutional business, which involves supplying anti-retroviral drugs to global agencies. Additionally, Strides benefits from its presence in regulated markets, where it garners substantial sales through its subsidiaries and strategic partnerships. The company also earns revenue from its foray into branded generics in select emerging markets and the sale of consumer healthcare products. Licensing agreements and collaborations with other pharmaceutical entities further contribute to its revenue, allowing for expanded market reach and access to advanced technologies.

Strides Pharma Science Ltd Financial Statement Overview

Summary

Strides Pharma Science Ltd shows a strong recovery in financial performance with improving profitability and cash management. The income statement indicates a strong recovery in net income and revenue growth, while the balance sheet shows a moderate debt-to-equity ratio and improved return on equity. However, historical volatility in net income and challenges in maintaining consistent cash flows suggest potential risks.

Income Statement

The income statement shows a strong recovery in net income and revenue growth in the latest period, indicating an improving trajectory. Gross profit margin and net profit margin have significantly improved, reflecting enhanced operational efficiency. However, historical volatility in net income and periods of negative EBIT and EBITDA margins suggest potential risks in maintaining consistent profitability.

Balance Sheet

The balance sheet presents a moderate debt-to-equity ratio, showing a balanced approach to leverage. The return on equity has improved substantially, signaling enhanced shareholder value creation. However, there is room for improvement in optimizing the equity ratio. The company faces challenges in maintaining a healthy cash position and managing liabilities effectively.

Cash Flow

The cash flow statement reflects strong free cash flow generation and positive operating cash flow, indicating solid cash management. The free cash flow to net income ratio suggests good conversion of profit into cash. Yet, fluctuations in free cash flow growth and historical challenges in maintaining consistent cash flows highlight potential risks.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	46.33B	46.24B	38.91B	36.68B	30.22B	32.51B
Gross Profit	19.33B	26.44B	21.66B	20.62B	14.39B	18.42B
EBITDA	8.62B	8.62B	3.76B	5.03B	-1.35B	7.25B
Net Income	3.34B	35.93B	-706.14M	-2.21B	-4.60B	2.68B
Balance Sheet
Total Assets	60.49B	60.49B	58.40B	66.38B	69.76B	70.15B
Cash, Cash Equivalents and Short-Term Investments	2.06B	2.06B	2.90B	3.61B	1.84B	2.75B
Total Debt	18.80B	18.80B	25.17B	30.30B	30.25B	23.48B
Total Liabilities	34.62B	34.62B	37.68B	44.66B	45.93B	42.01B
Stockholders Equity	25.52B	25.52B	21.26B	22.12B	23.59B	27.77B
Cash Flow
Free Cash Flow	0.00	4.42B	5.83B	-505.27M	-4.01B	1.84B
Operating Cash Flow	0.00	6.84B	7.01B	444.11M	-2.58B	4.81B
Investing Cash Flow	0.00	-896.89M	-1.50B	3.02B	-1.19B	-5.21B
Financing Cash Flow	0.00	-6.43B	-6.93B	-2.14B	4.21B	-157.96M

Strides Pharma Science Ltd Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 845.35
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:STAR, the sentiment is Neutral. The current price of 845.35 is below the 20-day moving average (MA) of 879.47, below the 50-day MA of 876.98, and above the 200-day MA of 741.82, indicating a neutral trend. The MACD of -1.08 indicates Positive momentum. The RSI at 43.26 is Neutral, neither overbought nor oversold. The STOCH value of 10.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:STAR.

Strides Pharma Science Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	76 Outperform	633.94B	19.01	10.68%	0.37%	7.76%	-2.84%
ALKEM	72 Outperform	666.69B	29.05	18.07%	0.81%	4.49%	11.22%
STAR	64 Neutral	₹79.05B	21.75		0.47%	10.84%	―
IPCALAB	63 Neutral	342.59B	45.43	10.62%	0.30%	11.49%	35.00%
GLENMARK	54 Neutral	569.42B	75.57	11.83%	0.12%	10.99%	0.00%
LAURUSLABS	54 Neutral	490.75B	96.47	8.01%	0.13%	17.31%	242.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%